Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verducatib Cardiac Safety Study in Healthy Participants
NCT07760246Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of verducatib (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: QT-interval corrected for heart rate change from baseline. Started Aug 2026; status: recruiting.
02
Drugs
verducatib
Beyond the preview
Go deeper on NCT07760246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07760246.